The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 348:2034-2035 May 15, 2003 Number 20
NextNext

The Use of Corticosteroids in SARS

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Lee, N.
-PubMed Citation
To the Editor: The use of systemic corticosteroids in patients with the severe acute respiratory syndrome (SARS) is of serious concern. Lee and colleagues report anecdotal success in their article on SARS elsewhere in this issue.1 And in the recent Web broadcast on SARS by the CDC, Dr. Sung, one of the coauthors, states, "High-dose steroid should be given early to stop the progression of the disease."2 The pathogenesis of SARS is diffuse alveolar damage with the acute respiratory distress syndrome (ARDS), not bronchiolitis obliterans with organizing pneumonia. And SARS is most likely due to coronavirus pneumonitis. Early treatment with . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.